Clinical trial NCT05602870: Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit
Official title: Acceptability of Advanced Chronic Liver Disease Screening by Transient Elstography (Fibroscan ®) in Patients Hospitalised in Psychiatric Unit: a Single Center Prospective Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Psychiatric Disorder
Psychiatric Hospitalization
Advanced Chronic Liver Disease
Liver Fibrosis
Keywords: psychiatric disorders
advanced liver disease
alcoholic liver diseases
viral hepatitis
transient elastography (Fibroscan ®)
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2022-11-02
Enrollment: 180
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders.

There are still many barriers to screening and linkage to care for patients having somatic illness.

Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs.

The aim of this study is to asses acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in a psychiatric unit.

Detailed description: Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders.

There are still many barriers to screening and linkage to care for patients having somatic illness.

Moreover follow-up of these patients may be difficult because of poor access to care, sometimes marginalization, and insufficient compliance with health programs.

Transient elastography is a useful tool validated for early diagnosis advanced chronic liver disease.It is non-invasive, fast, and gives immediate results.

The aim of this study is to assess acceptability of of advanced chronic liver disease screening by transient elstography (Fibroscan ®) in patients hospitalised in psychiatric unit.

Moreover, we will estimate de prevalence of advanced chronic liver diseases according to specific causes in psychiatry unit We hypothesize that the fact of offering psichiatric patents a non-invasive analysis of hepatic fibrosis will improve the detection of serious liver diseases and linkage to care.

Eligibility criteria: Inclusion criteria

* adults ≥18 years
* having a psychiatric condition and hospitalized in a psychiatry unit of CHU Montpellier , France
* patients who lack capacity of consent if legal representative consents
* involuntary psychiatric hospitalization, if consent is given

Exclusion criteria

* lack of written consent
* Unable to understand nature and objective of the methodology
* Pregnant or breast feeding woman
* Not affiliated with a French social security

Primary outcomes:
measure: acceptability of non invasive assessement of liver fibrosis by Fibroscan in psychiatric patients
timeFrame: At Inclusion
Secondary outcomes:
measure: Prevalence of advanced liver disease in psychiatric patients
timeFrame: At inclusion
measure: prevalence of excessive alcohol or drug consumption in psychiatric patients
timeFrame: At inclusion
measure: prevalence of passed or active drug consumption (intraveinous, inhaled or sniffed) in psychiatric patients
timeFrame: At Inclusion
measure: prevalence of viral hepatitis in psychiatric patients
timeFrame: At Inclusion
measure: correlation between advanced chronic liver diseases and risk factors for liver diseases in psychiatric patients
timeFrame: 1 to 3 month after inclusion
measure: assessment of referral to medical care when advanced fibrosis was diagnosed, regardless of its etiology
timeFrame: 1 to 3 month after inclusion
measure: reason for refusal of non invasive evaluation of chronic liver disease
timeFrame: At Inclusion
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Montpellier University Hospital
Study officials:
References: